Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 26888


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26888

License Grant
The Licensee has a non-exclusive licence to use a drug delivery technology which utilizes DepoFoam sustained injectable, inhalation and topical patented technologies from the British Licensor.

DepoFoam is a technology by which drugs taken by injection are formulated to release over an extended period of time.

Field of Use
The field of use relates to the drug industry.

IPSCIO Record ID: 314332

License Grant
Licensor grants to the Licensee of Denmark and its Affiliates a worldwide, exclusive license, with the right to sublicense, to the Licensed Patents and Licensed Know-How, to research, develop, make, have made, use, import, export, sell, offer for sale, and otherwise transfer the Licensed Product in the Territory.

Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoam® delivery system in order to develop and commercialize  formulations of Liraglutide.

License Property
Licensor is a biopharmaceutical company specializing in the discovery, development and commercialization of DepoFoam® a proprietary injectable sustained-release delivery system (multivesicular liposomes).

Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.

Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.

Field of Use
DepoFoam is a drug delivery technology which consists of multi-vesicular liposome particles that contain internal chambers for encapsulated drugs. DepoFoam is capable of sustained release of a drug over a period of between one and 30 days. It works with narrow gauge needles and pen systems and offers flexible delivery that can be designed to for an immediate release dose followed by sustained delivery.

IPSCIO Record ID: 27061

License Grant
The Company has previously agreed to pay royalties to CONSULTANT, a member of the Company's Board of Directors, in recognition of the patents developed by CONSULTANT for TIMERx.
License Property
The Company has developed the TIMERx delivery system, a novel drug delivery technology, to address the limitations of currently available oral controlled release delivery systems. The Company believes that the TIMERx system is a major advancement in oral drug delivery that represents the first easily-manufactured oral controlled release drug delivery system that is applicable to a wide variety of drug classes, including soluble drugs, insoluble drugs and drugs with a narrow therapeutic index. The Company is utilizing the TIMERx system to formulate generic versions of branded controlled release drugs, controlled release formulations of currently-marketed.

The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.

1)  Directly compressible sustained release excipient.

2)  Sustained release excipient and tablet formulation.

3)  Compressible sustained release solid dosage forms.

4)  EPO Application No. 89309518.2; filed September 19, 1989.

5)  Australian Patent Application No. 43057/89

6)  Japanese Patent Application No. 1-510135

7)  Irish Patent Application No. 2968/89

8)  Canadian Patent Application No. 611,700

9)  Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.

10)  2 U.S. Applications on Bi-modal release.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.